Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab.

I. Saulite; Emmanuella Guenova; Wolfram Hötzenecker

doi:10.1159/000478079

Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab.

Faculty of Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Original language	English
Title of host publication	Adverse Reactions to Biologics
Pages	70-81
Number of pages	12
Volume	53
DOIs	https://doi.org/10.1159/000478079
Publication status	Published - 2018

Publication series

Name	Current Problems in Dermatology (Switzerland)
ISSN (Print)	1421-5721

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Fields of science

303 Health Sciences
304 Medical Biotechnology
305 Other Human Medicine, Health Sciences
301 Medical-Theoretical Sciences, Pharmacy
302 Clinical Medicine

JKU Focus areas

Medical Sciences (in general)
Health System Research
Clinical Research on Aging

Access to Document

10.1159/000478079

Cite this

@inbook{2fcc60c13eb94b9898aaf14912cf74b3,

title = "Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab.",

author = "I. Saulite and Emmanuella Guenova and Wolfram H{\"o}tzenecker",

year = "2018",

doi = "10.1159/000478079",

language = "English",

volume = "53",

series = "Current Problems in Dermatology (Switzerland)",

pages = "70--81",

booktitle = "Adverse Reactions to Biologics",

}

Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab. / Saulite, I.; Guenova, Emmanuella ; Hötzenecker, Wolfram.
Adverse Reactions to Biologics. Vol. 53 2018. p. 70-81 (Current Problems in Dermatology (Switzerland)).

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

TY - CHAP

T1 - Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab.

AU - Saulite, I.

AU - Guenova, Emmanuella

AU - Hötzenecker, Wolfram

PY - 2018

Y1 - 2018

UR - https://www.ncbi.nlm.nih.gov/pubmed/29131039

UR - https://www.scopus.com/pages/publications/85033468467

U2 - 10.1159/000478079

DO - 10.1159/000478079

M3 - Chapter

VL - 53

T3 - Current Problems in Dermatology (Switzerland)

SP - 70

EP - 81

BT - Adverse Reactions to Biologics

ER -

Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab.

Publication series

UN SDGs

Fields of science

JKU Focus areas

Access to Document

Other files and links

Cite this